NIH R01 · 2025
Targeted degradation of CDK4 and 6 to overcome treatment resistance in breast cancer
Abstract Although CDK4/6 inhibitors (in combination with an endocrine therapy) are the preferred systemic therapy for treatment of patients with metastatic, Estrogen Receptor-positive (ER+) breast cancer (BC), development of resistance to CDK4/6 inhibitors is universal. Therefore, development of novel therapeutic strategies to target CDK4/6 inhibitor resistance remains an unmet clinical needs. To probe the dependency of ER+ BC cells and tumors on CDK4 and 6 for growth, we profiled a panel of ER+ BC cell lines, patient-derived xenografts (PDXs) and primary tumors from ER+ BC patients for expression of these proteins. We observed near universal expression of CDK4 but no detectable expression…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.